论文部分内容阅读
为了阐明α干扰素(α-INF)对毛细胞白血病(HCL)患者的临床和实验室治疗作用的机理,作者连续测定了3例用重组α-INF(rINF-α2)治疗的HCL患者的不同免疫学指标。3例HCL患者(2男,1女)的年龄分别为64岁、44岁和64岁,均未作脾切除术,以前也未治疗过。用rINF-α2治疗前,全部患者都有严重的中性粒细胞减少症(<500/μ1),其中2例患者同时有血小板减少症和轻度贫血。治疗方案为皮下注射2×10~6IU/m~2rINF-α2,每周3次。用药后2例出现发热,用朴热息痛加以控制。1例在治疗的第4周出现严重的中
To clarify the mechanism of alpha-INF in clinical and laboratory treatment of hair cell leukemia (HCL) patients, the authors continuously determined the difference in three HCL patients treated with recombinant alpha-INF (rINF-alpha2) Immunological indicators. Three patients with HCL (2 males and 1 females) were 64 years old, 44 years old and 64 years old, respectively. Neither was splenectomy nor previously treated. Prior to treatment with rINF-α2, all patients had severe neutropenia (<500 / μl), with 2 patients having both thrombocytopenia and mild anemia. Treatment regimens were subcutaneous injection of 2 × 10 ~ 6IU / m ~ 2rINF-α2, 3 times a week. 2 cases of fever after treatment, with Parkinson therapy to be controlled. One patient had a severe middle fourth week of treatment